Study opens discussion on use of plasma from female donors - Related Stories - AABB SmartBrief.
Noted this from my daily AABB SmartBrief. Transfusion-related acute lung injury (TRALI) has been a stubbornly enigmatic disease entity since being first described in detail about 25 years ago. Since antibody-associated TRALI (the most common and severe form) has almost exclusively been associated with women donors with a history of pregnancy, many centers have followed a straight-forward policy of excluding all female donors for plasma-rich products (e.g., FFP and apheresis platelets). The U.K. instituted this policy nationally in 2003. While in that country saw a decline of 66% in the incidence of "probable" TRALI and associated deaths in the three years following adoption of this policy, the price is exclusion of a large pool of donors. Further refinements of such a policy are in progress but perhaps this study might provoke a prospective study to be undertaken.
Noted this from my daily AABB SmartBrief. Transfusion-related acute lung injury (TRALI) has been a stubbornly enigmatic disease entity since being first described in detail about 25 years ago. Since antibody-associated TRALI (the most common and severe form) has almost exclusively been associated with women donors with a history of pregnancy, many centers have followed a straight-forward policy of excluding all female donors for plasma-rich products (e.g., FFP and apheresis platelets). The U.K. instituted this policy nationally in 2003. While in that country saw a decline of 66% in the incidence of "probable" TRALI and associated deaths in the three years following adoption of this policy, the price is exclusion of a large pool of donors. Further refinements of such a policy are in progress but perhaps this study might provoke a prospective study to be undertaken.
Recent Comments